Drug Sales Trends for ESTROGEL
Payment Methods and Pharmacy Types for ESTROGEL (2022)
Revenues by Pharmacy Type
Units Sold by Pharmacy Type
Annual Sales Revenues and Units Sold for ESTROGEL
| Drug Name | Revenues (USD) | Units | Year |
|---|---|---|---|
| ESTROGEL | ⤷ Start Trial | ⤷ Start Trial | 2022 |
| ESTROGEL | ⤷ Start Trial | ⤷ Start Trial | 2021 |
| ESTROGEL | ⤷ Start Trial | ⤷ Start Trial | 2020 |
| ESTROGEL | ⤷ Start Trial | ⤷ Start Trial | 2019 |
| >Drug Name | >Revenues (USD) | >Units | >Year |
EstroGel Market Analysis, Patent Status, Competitive Landscape, and Sales Projections
EstroGel is a prescription transdermal estradiol gel marketed in the United States by Ascend Therapeutics. The product contains estradiol 0.06% and delivers systemic estrogen through the skin for menopausal symptoms. Public sources do not report standalone EstroGel revenue, so the projections below are bottom-up estimates rather than company-reported sales.
The base case projects U.S. EstroGel net sales rising from approximately $55 million in 2025 to $78 million in 2030. Growth depends on continued demand for transdermal hormone therapy, stable reimbursement, patient preference for non-oral delivery, and the absence of a materially cheaper generic gel that captures most prescriptions.
What is EstroGel and how is it used?
EstroGel is a transdermal estradiol gel approved for systemic menopausal hormone therapy. The product is supplied in a metered-dose pump. One pump actuation delivers 1.25 grams of gel containing 0.75 mg of estradiol [1].
The U.S. label includes treatment of:
- Moderate-to-severe vasomotor symptoms associated with menopause.
- Moderate-to-severe symptoms of vulvar and vaginal atrophy associated with menopause.
Women with an intact uterus generally require an appropriate progestogen when systemic estrogen is prescribed, because unopposed estrogen increases the risk of endometrial hyperplasia and endometrial cancer [1].
EstroGel product profile
| Attribute | EstroGel detail |
|---|---|
| Active ingredient | Estradiol |
| Strength | 0.06% |
| Dosage form | Transdermal topical gel |
| U.S. dose delivery | 0.75 mg estradiol per pump actuation |
| Route | Topical, systemic transdermal absorption |
| U.S. regulatory status | Prescription drug |
| U.S. application | NDA 021166 |
| U.S. approval | 2004 |
| U.S. marketer | Ascend Therapeutics |
| Originator technology | Besins Healthcare transdermal estradiol platform |
| Main therapeutic area | Menopausal hormone therapy |
EstroGel competes on steady systemic estrogen delivery, avoidance of first-pass hepatic metabolism, and a non-patch administration format. Its weaknesses are application instructions, transfer precautions, skin-contact restrictions, and dependence on patient adherence.
What is the U.S. market for menopausal hormone therapy?
The U.S. menopausal hormone therapy market is mature but has regained demand since the decline in use that followed publication of the Women’s Health Initiative findings. Current clinical guidance emphasizes individualized treatment, symptom severity, age, time from menopause onset, route of administration, dose, and contraindications rather than a single treatment rule [2].
The addressable market includes:
- Systemic estrogen-only therapy for women without a uterus.
- Estrogen-progestogen therapy for women with a uterus.
- Local vaginal estrogen and other local therapies.
- Nonhormonal therapies for vasomotor symptoms.
- Transdermal patches, gels, sprays, and oral estradiol products.
Transdermal products have a commercial advantage in patients and prescribers seeking to avoid oral estrogen exposure. Clinical guidance recognizes that transdermal routes may have a lower effect on certain coagulation and triglyceride parameters than oral estrogen, although treatment selection remains patient-specific [2].
EstroGel is a niche product within systemic hormone therapy. Estradiol patches hold a larger share of transdermal prescribing because they are familiar, widely covered, and available from multiple generic manufacturers. EstroGel has a differentiated delivery format but operates in a price-sensitive category.
How much revenue does EstroGel generate?
Ascend Therapeutics does not publicly disclose EstroGel sales as a standalone product. The company is privately held, and available FDA materials do not provide commercial revenue data.
The following model estimates U.S. net sales using prescription volume, monthly treatment duration, and net realized price.
EstroGel sales projection
| Year | Low case | Base case | High case |
|---|---|---|---|
| 2024 estimated net sales | $39 million | $48 million | $60 million |
| 2025 projected net sales | $42 million | $55 million | $69 million |
| 2026 projected net sales | $44 million | $60 million | $76 million |
| 2027 projected net sales | $46 million | $64 million | $83 million |
| 2028 projected net sales | $48 million | $68 million | $90 million |
| 2029 projected net sales | $50 million | $73 million | $97 million |
| 2030 projected net sales | $52 million | $78 million | $105 million |
| 2025-2030 base-case CAGR | 7.2% |
The base case assumes prescription growth of approximately 3% to 5% annually, stable net pricing, and modest patient migration from oral estrogen and patches. The high case assumes improved coverage, stronger menopause-treatment demand, and successful retention of patients who prefer gel delivery. The low case assumes generic price pressure, payer restrictions, and continued substitution by estradiol patches.
These estimates represent commercial modeling rather than reported sales. They should not be interpreted as audited revenue.
Key revenue drivers
- Prescription growth. Greater medical engagement with menopause treatment could expand systemic hormone therapy use.
- Route preference. Patients seeking non-oral estrogen may select gel, patch, or spray products.
- Payer coverage. EstroGel’s revenue is sensitive to formulary tiering and prior authorization.
- Generic competition. Generic estradiol gel can reduce net price and increase substitution.
- Patient persistence. Gel products may retain patients who dislike patch adhesion or oral dosing.
- Commercial contracting. Rebates and specialty-pharmacy arrangements can materially reduce gross-to-net revenue.
What patents protect EstroGel?
EstroGel’s original product protection is mature. The U.S. product was approved in 2004, and any core patents covering the original estradiol gel technology would generally have reached or approached expiration by the mid-2020s, subject to patent-specific term adjustments, terminal disclaimers, and pediatric extensions.
The principal commercial barriers are therefore expected to be:
- Brand recognition.
- Prescriber familiarity.
- Formulation know-how.
- Manufacturing controls for dose uniformity.
- Patient support and adherence programs.
- Reimbursement access.
- Regulatory and manufacturing complexity.
EstroGel Orange Book status
The FDA Orange Book is the controlling source for current listed patents and exclusivity. EstroGel’s market position does not appear to depend on a long-dated, high-value patent estate comparable to newer specialty medicines. The principal NDA is 021166, while generic competition is governed through abbreviated new drug applications and any patents or exclusivities listed for the reference product [3].
An Orange Book listing, if present, would affect Paragraph IV timing and potential generic launch. A formulation patent that covers a specific gel composition, metered-dose pump, or manufacturing process could remain commercially relevant even after expiration of an older active-ingredient patent. Those rights would need to be evaluated claim by claim.
When does EstroGel lose exclusivity?
EstroGel’s key regulatory exclusivity period has expired. The product was approved in 2004, and the standard five-year new chemical entity exclusivity period would have ended no later than 2009 unless the product received a different regulatory classification. Any three-year exclusivity tied to a new clinical investigation would also have expired long ago [4].
Patent exclusivity is separate from FDA regulatory exclusivity. EstroGel’s commercial protection in the current market is more accurately characterized as post-exclusivity brand protection with generic competition than as an active innovator exclusivity period.
Generic entry scenarios
| Scenario | Market effect | EstroGel revenue effect |
|---|---|---|
| Limited generic availability | Generic captures price-sensitive patients, but brand retains continuity users | Moderate erosion |
| Multiple AB-rated generics | Payers prefer generic estradiol gel and increase substitution | High unit and price erosion |
| Generic manufacturing disruption | Brand maintains access and may recover share temporarily | Stable to positive |
| Narrowly differentiated generic | Substitution occurs mainly in formularies with mandatory generic use | Moderate erosion |
| Formulation or device dispute | Launch may be delayed or limited | Delayed erosion |
A generic launch does not automatically eliminate brand sales. EstroGel could retain patients who prefer the branded pump, have favorable coverage, or experience clinical or practical differences with alternative products. The strongest erosion would occur if multiple generic manufacturers enter and payers impose mandatory substitution.
Which companies compete with EstroGel?
EstroGel competes against several product classes rather than one direct rival.
Direct and near-direct competitors
| Product | Company or market source | Delivery | Competitive relationship |
|---|---|---|---|
| Generic estradiol gel | Multiple generic manufacturers | Gel | Closest substitute |
| Divigel | Vertical Pharmaceuticals and authorized distributors | Single-use gel packets | Direct gel competitor |
| Elestrin | Specialty/authorized marketers | Gel | Direct or near-direct gel competitor |
| Evamist | Dosing Technologies and commercial partners | Transdermal spray | Alternative transdermal format |
| Generic estradiol patches | Multiple manufacturers | Patch | Largest transdermal substitute |
| Vivelle-Dot generics | Multiple manufacturers | Patch | Broad payer competition |
| Oral estradiol | Multiple manufacturers | Tablet | Lower-cost systemic alternative |
| Climara generics | Multiple manufacturers | Weekly patch | Patch-based substitution |
Generic estradiol tablets are usually the most significant price competitor. Generic patches are the most relevant route competitor. Divigel and other gels compete more directly for patients who prefer topical application.
How strong is the EstroGel patent estate?
EstroGel’s patent estate is commercially moderate to weak compared with recently launched specialty drugs. The product has a long market history, an established formulation, and a known delivery system, but the original regulatory and patent barriers are mature.
Strengths
- Established FDA-approved product.
- Recognized transdermal route.
- Existing manufacturing and distribution infrastructure.
- Potential patient preference for gel over patches.
- Some practical switching friction once a patient is stable.
Weaknesses
- Estradiol is a long-established active ingredient.
- Several alternative dosage forms are available.
- Generic estradiol products are established.
- Core product exclusivity is expired.
- A clinical substitution can occur without complex physician education.
- Payer formularies can prioritize lower-cost alternatives.
The main defensible assets are likely formulation execution, metered-dose delivery, manufacturing reliability, brand continuity, and commercial access rather than broad composition-of-matter rights.
What FDA regulatory risks affect EstroGel?
EstroGel has no biosimilar risk because it is a small-molecule estradiol product, not a biologic. Competition occurs through the ANDA pathway rather than the biosimilar pathway [4].
The principal regulatory risks are:
- Manufacturing deviations affecting dose uniformity.
- Pump performance or container-closure issues.
- Labeling changes relating to estrogen risks.
- Postmarketing safety requirements.
- Application-transfer warnings.
- Accidental exposure to children or household contacts.
- Product shortages or supply interruptions.
The boxed warning for systemic estrogen products addresses risks including endometrial cancer, cardiovascular disorders, breast cancer, and probable dementia in certain populations. These warnings can affect prescribing and patient acceptance, even when the product remains approved [1].
What litigation and Paragraph IV risks affect EstroGel?
Public commercial risk is more likely to arise from generic approval and market access than from large-scale patent litigation. A generic applicant could file a Paragraph IV certification against any listed patent, triggering a patent dispute if the NDA holder files suit within the statutory period.
A Paragraph IV case could produce:
- A 30-month stay of final FDA approval under applicable conditions.
- Settlement with a delayed generic launch.
- License terms for an authorized generic.
- Litigation over formulation, device, or manufacturing claims.
- A judgment allowing immediate launch before patent expiration.
No litigation outcome should be assumed without reviewing the Federal Court docket, FDA Orange Book listings, and ANDA-specific public records. The existence of a generic estradiol gel market indicates that the basic dosage-form concept is not an effective long-term barrier.
How does EstroGel compare with estradiol patches?
| Factor | EstroGel | Estradiol patch |
|---|---|---|
| Application | Daily gel | Usually once or twice weekly |
| Adherence burden | Daily application | Lower dosing frequency |
| Skin issues | Possible transfer and contact precautions | Adhesion and skin irritation |
| Dosing flexibility | Can offer practical titration options | Fixed patch strengths |
| Payer competition | Moderate to high | High generic competition |
| Patient preference | Favored by some patients who dislike patches | Favored for convenience |
| Manufacturing complexity | Gel uniformity and pump delivery | Adhesive, matrix, and patch release |
| Generic pressure | Present | Strong and mature |
Patches have an adherence advantage because they require less frequent administration. EstroGel can differentiate where patients have patch adhesion problems, skin reactions, or a preference for gel application. The product is less defensible where payers treat all transdermal estradiol as therapeutically interchangeable.
What is the long-term commercial outlook for EstroGel?
The base case is stable growth at a low- to mid-single-digit rate, supported by renewed menopause-treatment utilization and the continuing role of transdermal estrogen. The principal downside is price erosion from generic estradiol gel and substitution by low-cost patches.
Commercial forecast by risk case
- Low case: U.S. net sales reach approximately $52 million by 2030. Generic competition and formulary pressure offset prescription growth.
- Base case: Sales reach approximately $78 million by 2030. EstroGel maintains a niche share among transdermal estrogen users.
- High case: Sales reach approximately $105 million by 2030. Coverage improves and demand grows among patients seeking non-oral estrogen.
International revenue could add value, but geographic performance depends on local brands, licensing arrangements, reimbursement systems, and whether EstroGel is marketed under the same name. U.S. sales should remain the primary analytical reference because U.S. product-level data and regulatory records are more accessible.
Key Takeaways
- EstroGel is a mature, FDA-approved transdermal estradiol gel marketed in the U.S. by Ascend Therapeutics.
- The product’s original exclusivity has expired, and its current value rests mainly on brand, formulation, delivery, manufacturing, and market-access assets.
- Public sources do not disclose standalone EstroGel revenue.
- Base-case U.S. net sales are estimated at $55 million in 2025 and $78 million in 2030.
- Generic estradiol gel and generic patches are the principal commercial threats.
- EstroGel has no biosimilar exposure because estradiol is a small molecule.
- The strongest launch-risk scenario is multiple generic entrants combined with mandatory payer substitution.
- The product’s competitive advantage is patient preference for gel delivery, not a long-dated patent barrier.
FAQs
Is EstroGel still patent protected?
EstroGel’s original product protection is mature. Any current protection would depend on specific Orange Book-listed patents covering formulation, delivery, device, or manufacturing claims.
Is there a generic version of EstroGel?
Generic estradiol gel products have entered the market. Availability, substitutability, and payer treatment vary by manufacturer, strength, distributor, and jurisdiction.
Is EstroGel more expensive than an estradiol patch?
Usually, generic estradiol patches and tablets create greater price pressure than branded EstroGel. Actual patient cost depends on insurance coverage, copay tier, deductible status, and pharmacy channel.
Can EstroGel be used without progesterone?
Women with an intact uterus generally require endometrial protection when using systemic estrogen. The decision depends on the prescribed regimen and clinical circumstances.
What would most increase EstroGel sales?
The strongest growth drivers would be expanded insurance coverage, greater use of transdermal hormone therapy, favorable formulary placement, improved patient persistence, and limited generic substitution.
References
- U.S. Food and Drug Administration. (2023). EstroGel (estradiol gel) 0.06% prescribing information.
- The North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767-794.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Generic drug facts and abbreviated new drug application pathway.
More… ↓
